Paper Details

  1. Home
  2. Paper Details

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report.

Author: DuanJianchun, LiShuluan, WangJie, WangTianyu, ZhangPei

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This case report describes the successful use of brigatinib, an anaplastic lymphoma kinase (ALK) inhibitor, in a patient with ALK-positive lung squamous cell carcinoma (sqCC). The patient achieved a response lasting approximately 11 months with tolerable side effects, suggesting that ALK inhibitors may be effective in ALK-positive sqCC.
Paper Details　
Original Abstract of the Article :
The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636200/

データ提供：米国国立医学図書館（NLM）

Brigatinib: A Potential Hope for Lung Squamous Cell Carcinoma

Lung cancer research continues to be a vast and ever-expanding desert, where we, as researchers, are constantly searching for new oases of hope. This study focuses on anaplastic lymphoma kinase (ALK) positive lung squamous cell carcinoma (sqCC), a specific type of lung cancer. It explores the potential of brigatinib, an ALK inhibitor, as a treatment option. The researchers employed a case study approach to analyze the effectiveness of brigatinib in a patient with ALK-positive lung squamous cell carcinoma and brain metastases. They observed a positive response duration of approximately 11 months, with manageable side effects. This research provides valuable insights into the potential benefits of brigatinib for patients with this specific form of lung cancer.

Brigatinib: A Promising Treatment for ALK-Positive Lung Squamous Cell Carcinoma

The study's results demonstrate the effectiveness of brigatinib in treating a patient with ALK-positive lung squamous cell carcinoma. This finding suggests that brigatinib could be a promising treatment option for individuals with this specific type of lung cancer. The observed response duration of 11 months, coupled with manageable side effects, further strengthens this possibility. It's important to note that this research is based on a single case study, and larger clinical trials are needed to confirm these findings and fully explore the potential of brigatinib in this context.

Brigatinib: A Glimpse of Hope in the Lung Cancer Landscape

The results of this case study offer a glimmer of hope in the challenging landscape of lung cancer. While further research is needed, the positive outcome in this patient suggests that brigatinib could be a valuable tool in the fight against this devastating disease. This research underscores the importance of targeted therapies, like ALK inhibitors, in providing personalized and effective treatment options for patients with specific genetic mutations.

Dr.Camel's Conclusion

This case study provides a promising glimpse into the potential of brigatinib as a treatment for ALK-positive lung squamous cell carcinoma. The study's findings, while based on a single case, suggest that brigatinib could offer a new avenue for treatment and a potential oasis of hope for patients battling this type of cancer.
Date :
  1. Date Completed 2022-01-31
  2. Date Revised 2022-01-31
Further Info :

Pubmed ID

34647426

DOI: Digital Object Identifier

PMC8636200

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.